Can we avoid chemotherapy entirely in follicular lymphoma?
Lymphoma Hub9 Nov 2020

Can we avoid chemotherapy entirely in follicular lymphoma?

During the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Nathan Fowler, MD Anderson Cancer Center, Houston, US, who discussed the non-chemotherapy approaches to treating follicular lymphoma.


Treatment for follicular lymphoma has been improving over recent years. The addition of rituximab, an anti-CD20 antibody, to the clinician's arsenal has been a real game changer in the field. Nathan Fowler describes its mode of action and the role it plays in modern treatment strategies.


Fowler discusses the different courses the disease can take and how therapy can be tailored to suit an individual's needs. The current treatment standards and the response rates achieved with these agents are examined.


Lenalidomide, an immunomodulatory drug, in combination with rituximab was investigated in comparison to three different chemotherapy regimes in the RELEVANCE trial, and Fowler details the outcomes of this study. The differing adverse events experienced by patients following these therapies are listed. He goes on to say how this result has influenced his clinical practice and how the presence of high-risk factors impacts treatment decision making.


Nathan Fowler rounds off his talk by introducing other non-chemotherapy options, such as obinutuzumab, Pi3 kinase inhibitors, tazemetostat, and chimeric antigen receptor (CAR) T cells.

Hosted on Acast. See acast.com/privacy for more information.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(53)

Symposium |Optimizing chronic lymphocytic leukemia management in a changing landscape

Symposium |Optimizing chronic lymphocytic leukemia management in a changing landscape

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee mem...

20 Aug 23min

Symposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence

Symposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Farrukh Awan, University of Texas S...

12 Aug 27min

Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs

Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee mem...

12 Aug 12min

EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?

EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?

The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY 2-EU trial of zamtocabtagene autoleucel ...

21 Juli 8min

EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?

EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?

Following the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We...

16 Juli 10min

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial

During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III SEQUOIA trial (NCT03336333) evaluating za...

10 Juli 26min

EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?

EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Stephen Schuster, University of Pennsylvania, Philadelphia, US. We asked, W...

1 Juli 5min

Annual oncology meeting | Key highlights in lymphoma

Annual oncology meeting | Key highlights in lymphoma

During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount ...

22 Juni 11min

Populärt inom Utbildning

historiepodden-se
det-skaver
rss-bara-en-till-om-beroende-medberoende
nu-blir-det-historia
not-fanny-anymore
roda-vita-rosen
allt-du-velat-veta
harrisons-dramatiska-historia
rss-viktmedicinpodden
rikatillsammans-om-privatekonomi-rikedom-i-livet
johannes-hansen-podcast
sa-in-i-sjalen
rss-max-tant-med-max-villman
i-vantan-pa-katastrofen
rss-foraldramotet-bring-lagercrantz
rss-ar-det-rimligt
sektledare
rss-sjalsligt-avkladd
sex-pa-riktigt-med-marika-smith
rss-traningsklubben